Editas Medicine, Inc.: Form 10-Q for the period ended Sep 30, 2017
Filed with the SEC on Nov 8, 2017 and accepted by EDGAR at Nov 7, 2017, 17:39 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2017-07-01 to 2017-09-30 | $20.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2017-01-01 to 2017-09-30 | $56.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2017-07-01 to 2017-09-30 | −$26.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2017-01-01 to 2017-09-30 | −$83.5m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2017-07-01 to 2017-09-30 | −$26.6m | us-gaap:NetIncomeLoss |
| Net income | 9 months2017-01-01 to 2017-09-30 | −$84.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-07-01 to 2017-09-30 | −$0.64 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2017-01-01 to 2017-09-30 | −$2.13 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months2017-01-01 to 2017-09-30 | $15.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2017-01-01 to 2017-09-30 | $1.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2017-09-30 | $86.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-09-30 | $298.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-09-30 | $339.1m | us-gaap:Assets |
| Current liabilities | At period end2017-09-30 | $29.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-09-30 | $161.3m | us-gaap:Liabilities |
| Shareholders' equity | At period end2017-09-30 | $177.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-17-008429. Last ingested by Listed: Nov 6, 2026, 17:42 ET. Listed shows no prices and gives no investment advice.